Your browser doesn't support javascript.
loading
Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis.
Prakash, Annamneedi Venkata; Park, Jun Woo; Seong, Ju-Won; Kang, Tae Jin.
Afiliação
  • Prakash AV; Convergence Research Center, Department of Pharmacy and Institute of Chronic Disease, Sahmyook University, Seoul 01795, Republic of Korea.
  • Park JW; Convergence Research Center, Department of Pharmacy and Institute of Chronic Disease, Sahmyook University, Seoul 01795, Republic of Korea.
  • Seong JW; Convergence Research Center, Department of Pharmacy and Institute of Chronic Disease, Sahmyook University, Seoul 01795, Republic of Korea.
  • Kang TJ; Convergence Research Center, Department of Pharmacy and Institute of Chronic Disease, Sahmyook University, Seoul 01795, Republic of Korea.
Biomol Ther (Seoul) ; 28(3): 222-229, 2020 May 01.
Article em En | MEDLINE | ID: mdl-32133828
ABSTRACT
The process of drug discovery and drug development consumes billions of dollars to bring a new drug to the market. Drug development is time consuming and sometimes, the failure rates are high. Thus, the pharmaceutical industry is looking for a better option for new drug discovery. Drug repositioning is a good alternative technology that has demonstrated many advantages over de novo drug development, the most important one being shorter drug development timelines. In the last two decades, drug repositioning has made tremendous impact on drug development technologies. In this review, we focus on the recent advances in drug repositioning technologies and discuss the repositioned drugs used for inflammatory diseases such as sepsis, asthma, and atopic dermatitis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article